HOME >> BIOLOGY >> NEWS
Oxygen key switch in transforming adult stem cells from fat into cartilage

NEW ORLEANS -- In their ongoing research on turning adult stem cells isolated from fat into cartilage, Duke University Medical Center researchers have demonstrated that the level of oxygen present during the transformation process is a key switch in stimulating the stem cells to change.

Their findings were presented today (Feb. 2, 2003) at the annual meeting of the Orthopedic Research Society.

Using a biochemical cocktail of steroids and growth factors, the researchers have "retrained" specific adult stem cells that would normally form the structure of fat into another type of cell known as a chondrocyte, or cartilage cell. During this process, if the cells were grown in the presence of "room air," which is about 20 percent oxygen, the stem cells tended to proliferate; however, if the level of oxygen was reduced to 5 percent, the stem cells transformed into chondrocytes.

This finding is important, the researchers say, because this low oxygen level more closely simulates the natural conditions of cartilage, a type of connective tissue that cushions many joints throughout the body. However, since it is a tissue type poorly supplied by blood vessels, nerves and the lymphatic system, cartilage has a very limited capacity for repair when damaged. For this reason, the Duke investigators are searching for a bioengineering approach to correct cartilage injury.

"Our findings suggest that oxygen is a key determinant between proliferation and differentiation, and that hypoxia, or low oxygen levels, is an important switch that tells cells to stop proliferating and start differentiating,' said David Wang, a fourth-year medical student at Duke, who presented the results of the Duke research.

Farshid Guilak, Ph.D., director of orthopedic research and senior member of the Duke team, said that the combination of growth factors sets the adult stem cells on the right path, while controlling oxygen levels inspires the cells to more readily transf
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
2-Feb-2003


Page: 1 2 3

Related biology news :

1. Oxygen sensing in worms may hold key to healthy blood pressure in humans
2. Oxygen triggered the evolution of complex life forms
3. Oxygen deficiency is an endocrine disruptor in fish
4. Evolution upset: Oxygen-making microbes came last, not first
5. Oxygen is toxic to stem cells
6. Oxygen measurements yield greenhouse clues
7. Tumor Oxygen Level And Blood Flow Fluctuate, Duke Scientists Discover
8. Fake Photosynthesis? Test-Tube System In Science Paper Sheds Light On The Oxygen We Breathe, UD Prof Says
9. Oxygen-Carrying Myoglobin Not Necessary For Survival
10. Stroke Risk Increased In Patients With High Oxygen Use In Brain
11. Improved Oxygen Bath To Heal Wounds, Lessen Number Of Amputations: Sandia To Sign Agreement With Numotech To Help Create Home-Use Healing Facility

Post Your Comments:
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: